Abbey Donald
Known title: DirectorCIK: 0001534342
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
Transaction History
| ICUI | ▲ Buy | Option Exercise | 1,254 | $0 | 5/13/2026 | View on chart |
| ICUI | ▼ Sell | Other | 704 | $0 | 3/25/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,723 | $0 | 5/13/2025 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 948 | $0 | 5/15/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 485 | $0 | 5/17/2023 | View on chart |
| DXCM | ▼ Sell | Other | 3,604 | $401K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 4,675 | $521K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 3,390 | $378K | 3/10/2023 | View on chart |
| DXCM | ▲ Buy | Grant | 18,776 | $19 | 3/8/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 433 | $0 | 5/11/2022 | View on chart |
| DXCM | ▼ Sell | Other | 1,317 | $535K | 3/9/2022 | View on chart |
| DXCM | ▼ Sell | Other | 932 | $378K | 3/9/2022 | View on chart |
| DXCM | ▼ Sell | Other | 1,180 | $479K | 3/9/2022 | View on chart |
| DXCM | ▲ Buy | Grant | 4,984 | $5 | 3/8/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 1,248 | $676K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 15 | $8K | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ICU Medical Highlighted in Zacks Industry Outlook
ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.
ICU Medical Highlighted in Zacks Industry Outlook. ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.